Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

NCT04246723 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT04246723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04246723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Lead sponsor
R-Pharm
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2019
Completion date
August 12, 2020
Enrollment
85 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c genotype 1